Clinical Trial: Palmitoylethanolamide Modulates Central Sensitisation and Neuroinflammation in Chronic Low Back Pain

U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07772141) titled 'Palmitoylethanolamide Modulates Central Sensitisation and Neuroinflammation in Chronic Low Back Pain' on Aug. 12.

Brief Summary: Low back pain (LBP) is a public and occupational health problem that is a major professional, economic and social burden. Up to 84% of the general population will experience an episode of LBP during its life time, and recurrence rates are high. Acute LBP is the second reason for consultations in general medicine, and chronic LBP is the eighth. One in five LBP episodes result in sick leave. LBP represents 30% of sick leaves that are longer than 6 months, and 20% of work accidents. LBP has become the leading...